0001493152-23-017905.txt : 20230517 0001493152-23-017905.hdr.sgml : 20230517 20230517102337 ACCESSION NUMBER: 0001493152-23-017905 CONFORMED SUBMISSION TYPE: AW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230517 DATE AS OF CHANGE: 20230517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ensysce Biosciences, Inc. CENTRAL INDEX KEY: 0001716947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822755287 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: AW SEC ACT: SEC FILE NUMBER: 333-271480 FILM NUMBER: 23929969 BUSINESS ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 263-4196 MAIL ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Leisure Acquisition Corp. DATE OF NAME CHANGE: 20170913 AW 1 formaw.htm

Ensysce Biosciences, Inc.

7946 Ivanhoe Avenue, Suite 201

La Jolla, California 92037

May 17, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

Re:

Ensysce Biosciences, Inc.

Post-Effective Amendment No. 1 to Registration Statement on Form S-1

Withdrawal Request – Form type “AW”

SEC File No. 333-271480

Ladies and Gentlemen:

Pursuant to Rule 477(a) of the Securities Act of 1933, as amended (the “Securities Act”), Ensysce Biosciences, Inc. (the “Company”) hereby requests withdrawal of above referenced Post-Effective Amendment (the “Post-Effective Amendment”) filed May 12, 2023. The Post-Effective Amendment was filed pursuant to Rule 462(d) of the Securities Act solely to file exhibits but was erroneously coded and filed as a form type “POS AM”, rather than “POS EX”, with an incorrect file number provided immediately after the Rule 462(d) box checked on the cover page of the Post-Effective Amendment. As a result, the Company wishes to withdraw the Post-Effective Amendment. Shortly after submission of this Form AW, the Company will refile a nearly identical, properly coded, post-effective amendment.

The Company requests that the Commission consent to this request on the basis that withdrawal of the Post-Effective Amendment is consistent with the public interest and the protection of investors.

Please direct any questions or comments concerning this request to Gregory Rubis, Esq. ((609) 951-4105) of Troutman Pepper Hamilton Sanders LLP.

	ENSYSCE BIOSCIENCES, INC.

	By:	/s/ Lynn Kirkpatrick
	Name:	Lynn Kirkpatrick
	Title:	CEO

Cc:	Eric D. Kline, Troutman Pepper Hamilton Sanders LLP
	Gregory Rubis, Troutman Pepper Hamilton Sanders LLP